Intracerebroventricular passive immunization with anti-Aβ antibody in Tg2576

Journal of Neuroscience Research

Volumn 74, Issue 1, 2003, Pages 142-147

  Chauhan, Neelima B ^a,b   Siegel, George J ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Cerebral hemorrhage; Immunotherapy; Inflammation; Intracerebroventricular passive immunization

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; ANTIBODY; INTERLEUKIN 1BETA; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; MACROGLIA; MENINGOENCEPHALITIS; MICROGLIA; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 0141758165     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10721     Document Type: Article

References (39)

1. Atwood CS, Perry G, Smith MA. 2003. Cerebral hemorrhage and amyloid-beta. Science 299:1014.
2. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 6:916-919.
3. Chauhan NB, Siegel GJ. 2002. Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. J Neurosci Res 69:10-23.
4. Chauhan NB, Siegel GJ, Lichtor T. 2001. Distribution of intraventricularly administered antiamyloid-beta peptide (Abeta) antibody in the mouse brain. J Neurosci Res 66:231-235.
5. Das P, Paul M, Murphy LH, Younkin S, Younkin G, Golde TE. 2001. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22:721-727.
6. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
7. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5:452-457.
8. Frenkel D, Katz O, Solomon B. 2000. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA 97:11455-11459.
9. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G. 2003. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126(Pt 2):285-291.
10. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. 1992. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357:500-503.
11. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Home P, Heslin D, French J, Mount HT, Nixon, RA, Mercken M, Bergeron C, Fraser PE, St. George-Hyslop P, Westaway D. 2000. A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
12. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736.
13. Kemper TL. 1994. Neuroanatomical and neuropathological changes during aging and dementia. In: Albert ML, Knoefel JE, editors. Clinical neurology of aging, 2nd ed. New York: Oxford University Press. p 3-67.
14. Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, Roher AE. 2000. Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med 6:430-439.
15. Masliah E, Mallory M, Ge N, Saitoh T. 1992. Amyloid precursor protein is localized in growing neurites of neonatal rat brain. Brain Res 593:323-328.
16. McGeer PL, McGeer E. 2003. Is there a future for vaccination as a treatment for Alzheimer's disease? Neurobiol Aging 24:391-395.
17. Mills J, Reiner PB. 1999. Regulation of amyloid precursor protein cleavage. J Neurochem 72:443-460.
18. Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM. 2002. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 277:33012-33017.
19. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
20. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med [epub ahead of print].
21. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. 2002. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379.
22. Sainte-Rose C, Cinalli G, Roux FE, Maixner R, Chumas PD, Mansour M, Carpentier A, Bourgeois M, Zerah M, Pierre-Kahn A, Renier D. 2001. Management of hydrocephalus in pediatric patients with posterior fossa tumors: the role of endoscopic third ventriculostomy. J Neurosurg 95:791-797.
23. Schenk D. 2002. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3:824-828.
24. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee, M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
25. Selkoe DJ. 1994. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17:489-517.
26. Selkoe DJ. 1996. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271:18295-18298.
27. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormak R, Wolfert R, Selkoe D, Lieberberg I, Schenk D. 1992. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359:325-327.
28. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. 2001. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159:439-447.
29. Sigurdsson EM, Wisniewski T, Frangione B. 2002. A safer vaccine for Alzheimer's disease? Neurobiol Aging 23:1001-1008.
30. Simons M, Keller P, Dichgans J, Schulz JB. 2001. Cholesterol and Alzheimer's disease: is there a link? Neurology 57:1089-1093.
31. Siomin V, Cinalli G, Grotenhuis A, Golash A, Oi S, Kothbauer K, Weiner H, Roth J, Beni-Adani L, Pierre-Kahn A, Takahashi Y, Mallucci C, Abbott R, Wisoff J, Constantini S. 2002. Endoscopic third ventriculostomy in patients with cerebrospinal fluid infection and/or hemorrhage. J Neurosurg 97:519-524.
32. Smith MA, Atwood CS, Joseph JA, Perry G. 2002. Predicting the failure of amyloid-beta vaccine. Lancet 359:1864-1865.
33. Solomon B. 2001. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol 20:697-703.
34. Solomon B. 2002. Towards Alzheimer's disease vaccination. Mini Rev. Med Chem 2:85-92.
35. Solomon B, Koppel R, Hanan E, Katzav T. 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA 93:452-455.
36. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. 1997. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94:4109-4112.
37. Weiner HL, Selkoe DJ. 2002. Inflammation and therapeutic vaccination in CNS diseases. Nature 420:879-884.
38. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ. 2000. Nasal administration of amyloid-b peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48:567-579.
39. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. 2003. Intracranially administered anti-abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23:3745-3751.